<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="56345">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02372630</url>
  </required_header>
  <id_info>
    <org_study_id>514091</org_study_id>
    <nct_id>NCT02372630</nct_id>
  </id_info>
  <brief_title>The Effect of LINAGLIPTIN on Inflammation, Oxidative Stress and Insulin Resistance in Obese Type 2 Diabetes Subjects</brief_title>
  <acronym>1971</acronym>
  <official_title>The Effect of TRADJENTA ® (LINAGLIPTIN) on Inflammation, Oxidative Stress and Insulin Resistance in Obese Type 2 Diabetes Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University at Buffalo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kaleida Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University at Buffalo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single center, prospective randomized double blind, parallel and placebo
      controlled study to evaluate oxidative stress and inflammation before and after treatment
      with linagliptin for 12 weeks. We will also, testing whether Linagliptin is an insulin
      sensitizer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">August 2016</completion_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in JNK-1 protein in MNC before and after linagliptin use as compared to placebo.</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in inflammatory mediators in serum and adipose tissue following 12 weeks of treatments compared to placebo.</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in inflammation and oxidative stress following a single does of linagliptin.</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in insulin sensitivity following linagliptin treatment compared to placebo.</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will be treated for 12 weeks with placebo once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Linagliptin 5mg per day</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will be treated for 12 weeks with Linagliptin 5mg once daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linagliptin</intervention_name>
    <arm_group_label>Linagliptin 5mg per day</arm_group_label>
    <other_name>TRADJENTA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Age 20-80 years inclusive. Type 2 diabetes BMI ≥30 kg/m2 Subjects on statins, ACE
        inhibitors, thiazolidenediones and antioxidants will be allowed as long as they are on
        stable doses of these compounds and the dosage in not changed during the course of study.

        HbA1c ≤ 8.0%

        Exclusion Criteria:

        - Use of GLP-1 agonists or DPP-IV therapy in the last 3 months. History of Pancreatitis.
        Risk for pancreatitis, i.e., history of gallstones, alcohol abuse, and
        hypertriglyceridemia.

        Subjects who are taking antiplatelet or anticoagulant medications will be excluded from
        the fat biopsy portion of the study.

        Coronary event or procedure (myocardial infarction, unstable angina, coronary artery
        bypass, surgery or coronary angioplasty) in the previous four weeks Hepatic disease (liver
        function tests more than 3 times the upper limit of normal) Renal impairment (serum eGFR
        &lt;30 ml/min) Any other life-threatening, non-cardiac disease Uncontrolled hypertension (BP
        &gt; 160/100 mm of Hg) Congestive Heart Failure class III or IV. Use of an investigational
        agent or therapeutic regimen within 30 days of study Participation in any other concurrent
        clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Paresh Dandona, MD</last_name>
    <phone>716-898-1940</phone>
    <email>pdandona@kaleidahealth.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jeanne Hejna, LPN</last_name>
    <phone>716-898-1944</phone>
    <email>jeannehe@buffalo.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>ECMC Ambulatory Center, 3rd Floor</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paresh Dandona, MD</last_name>
      <phone>716-898-1940</phone>
      <email>pdandona@kaleidahealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Jeanne Hejna, LPN</last_name>
      <phone>716-898-1944</phone>
      <email>jeannehe@buffalo.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <lastchanged_date>May 10, 2016</lastchanged_date>
  <firstreceived_date>February 20, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University at Buffalo</investigator_affiliation>
    <investigator_full_name>Paresh Dandona</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Linagliptin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
